Advertisement
Canada markets open in 5 hours 42 minutes

  • S&P/TSX

    22,290.62
    +31.15 (+0.14%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • DOW

    38,884.26
    +31.99 (+0.08%)
     

  • CAD/USD

    0.7271
    -0.0015 (-0.21%)
     

  • CRUDE OIL

    77.61
    -0.77 (-0.98%)
     

  • Bitcoin CAD

    85,731.01
    -1,845.52 (-2.11%)
     

  • CMC Crypto 200

    1,289.02
    -5.65 (-0.44%)
     

  • GOLD FUTURES

    2,319.20
    -5.00 (-0.22%)
     

  • RUSSELL 2000

    2,064.65
    +3.97 (+0.19%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • NASDAQ futures

    18,206.25
    +6.75 (+0.04%)
     

  • VOLATILITY

    13.22
    -0.01 (-0.08%)
     

  • FTSE

    8,350.90
    +37.23 (+0.45%)
     

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • CAD/EUR

    0.6767
    -0.0004 (-0.06%)
     

Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Business Wire
·2 min read

TORONTO, April 08, 2024--(BUSINESS WIRE)--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16th and 17th in Toronto.

Mr. Frank Gleeson, Co-founder and CEO of Satellos, will provide a corporate presentation on Tuesday, April 16, 2024, at 11:30 a.m. ET and will participate in one-on-one meetings during the conference along with the management team of Satellos. The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the presentation.

About Satellos Bioscience Inc.

Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408765814/en/

Contacts

Investors: Liz Williams, ir@satellos.com
Business Development: Ryan Mitchell, Ph.D., bd@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091